Clinical Trials Logo

Phobia, Social clinical trials

View clinical trials related to Phobia, Social.

Filter by:

NCT ID: NCT00318669 Completed - Social Phobia Clinical Trials

Social Anxiety Disorder Study Of Paroxetine

Start date: December 2005
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD).

NCT ID: NCT00273039 Completed - Anxiety Disorders Clinical Trials

A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder

Start date: August 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the safety and efficacy of GW679769 and paroxetine in subjects with Social Anxiety Disorder

NCT ID: NCT00246441 Completed - Clinical trials for Alcohol Use Disorder

Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism

Start date: March 2002
Phase: Phase 4
Study type: Interventional

The purpose of the study is to determine whether an SSRI, paroxetine, improves social anxiety symptoms and alcohol use in individuals who drink to cope with social anxiety disorder.

NCT ID: NCT00182533 Terminated - Clinical trials for Major Depressive Disorder

Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders

Start date: July 2002
Phase: Phase 4
Study type: Interventional

Selective serotonin reuptake inhibitors (SSRIs) including sertraline have been found to be effective in the treatment of generalized social phobia (GSP). However, virtually all of the current treatment studies with medicines, including the SSRIs, have excluded patients with social phobia who have other co-occurring conditions. In fact, 80% of individuals suffering with primary social phobia have at least one other anxiety. This study will evaluate the safety and efficacy of sertraline in the treatment of generalized social phobia with co-occurring anxiety and mood disorders.

NCT ID: NCT00182455 Terminated - Social Phobia Clinical Trials

Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP)

Start date: March 1, 2004
Phase: Phase 4
Study type: Interventional

SSRI's are considered first-line treatments for GSP, however many patients continue to have significant symptoms despite an adequate trial of an SSRI. Topiramate, a drug, which targets the glutamate system in the brain, has been shown to improve symptoms of social phobia when used on its own and has also been used as an additive treatment in other anxiety disorders. This study will test the efficacy of adding topiramate to a subject's current SSRI in cases of GSP which are considered to be treatment-resistant.

NCT ID: NCT00141115 Completed - Anxiety Disorders Clinical Trials

Levetiracetam for the Treatment of Alcohol Dependence and Anxiety

Start date: March 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if levetiracetam is effective in treating alcohol dependence in patients with anxiety symptoms. The researchers hypothesize that individuals are unable to reduce or discontinue alcohol use because of significant anxiety, mood, and sleep disturbance symptoms that accompany reduction in alcohol use.

NCT ID: NCT00000370 Completed - Social Phobia Clinical Trials

Treatment of Social Phobia

Start date: May 1998
Phase: N/A
Study type: Interventional

Social phobia is a very common and debilitating disorder, with public speaking anxiety being the most common fear. Psychologists have found that treating patients for their fear of public speaking, through cognitive-behavioral treatment (talk-based therapy) or exposure treatment (where participants participate in actual public speaking sessions), not only helps patients overcome this fear but also helps them overcome their more general social fears. However, little is known about how this change occurs during therapy. This study tries to identify the factors that contribute most to successful therapy. Patients are assigned randomly (like tossing a coin) to 1 of 3 groups. Group 1 will receive cognitive-behavioral treatment and Group 2 will receive exposure treatment. Group 3 will not receive treatment. Study leaders will monitor patient response to treatment through behavioral tests and assessments. An individual may be eligible for this study if he/she: Has social phobia with public speaking anxiety.